FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910130606> ?p ?o ?g. }

• W2910130606 endingPage "e0210105" @default.
• W2910130606 startingPage "e0210105" @default.
• W2910130606 abstract "Cryptococcal meningitis accounts for 15% of AIDS-related mortality. Cryptococcal antigen (CrAg) is detected in blood weeks before onset of meningitis, and CrAg positivity is an independent predictor of meningitis and death. CrAg screening for patients with advanced HIV and preemptive treatment is recommended by the World Health Organization, though implementation remains limited. Our objective was to evaluate costs and mortality reduction (lives saved) from a national CrAg screening program across Uganda.We created a decision analytic model to evaluate CrAg screening. CrAg screening was considered for those with a CD4<100 cells/μL per national and international guidelines, and in the context of a national HIV test-and-treat program where CD4 testing was not available. Costs (2016 USD) were estimated for screening, preemptive therapy, hospitalization, and maintenance therapy. Parameter assumptions were based on large prospective CrAg screening studies in Uganda, and clinical trials from sub Saharan Africa. CrAg positive (CrAg+) persons could be: (a) asymptomatic and thus eligible for preemptive treatment with fluconazole; or (b) symptomatic with meningitis with hospitalization.In the base case model for 1 million persons with a CD4 test annually, 128,000 with a CD4<100 cells/μL were screened, and 8,233 were asymptomatic CrAg+ and received preemptive therapy. Compared to no screening and treatment, CrAg screening and treatment in the base case cost $3,356,724 compared to doing nothing, and saved 7,320 lives, for a cost of $459 per life saved, with the $3.3 million in cost savings derived from fewer patients developing fulminant meningitis. In the scenario of a national HIV test-and-treat program, of 1 million HIV-infected persons, 800,000 persons were screened, of whom 640,000 returned to clinic, and 8,233 were incident CrAg positive (CrAg prevalence 1.4%). The total cost of a CrAg screening and treatment program was $4.16 million dollars, with 2,180 known deaths. Conversely, without CrAg screening, the cost of treating meningitis was $3.09 million dollars with 3,806 deaths. Thus, despite the very low CrAg prevalence of 1.4% in the general HIV-infected population, and inadequate retention-in-care, CrAg screening averted 43% of deaths from cryptococcal meningitis at a cost of $662 per death averted.CrAg screening and treatment programs are cost-saving and lifesaving, assuming preemptive treatment is 77% effective in preventing death, and could be adopted and implemented by ministries of health to reduce mortality in those with advanced HIV disease. Even within HIV test-and-treat programs where CD4 testing is not performed, and CrAg prevalence is only 1.4%, CrAg screening is cost-effective." @default.
• W2910130606 created "2019-01-25" @default.
• W2910130606 creator A5009824461 @default.
• W2910130606 creator A5019572541 @default.
• W2910130606 creator A5027410574 @default.
• W2910130606 creator A5039731580 @default.
• W2910130606 creator A5044274628 @default.
• W2910130606 creator A5060071132 @default.
• W2910130606 creator A5079155294 @default.
• W2910130606 creator A5090161266 @default.
• W2910130606 date "2019-01-10" @default.
• W2910130606 modified "2023-10-10" @default.
• W2910130606 title "Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis" @default.
• W2910130606 cites W2034630867 @default.
• W2910130606 cites W2101195119 @default.
• W2910130606 cites W2102545142 @default.
• W2910130606 cites W2105745780 @default.
• W2910130606 cites W2107740974 @default.
• W2910130606 cites W2108521877 @default.
• W2910130606 cites W2113417401 @default.
• W2910130606 cites W2115326218 @default.
• W2910130606 cites W2127250507 @default.
• W2910130606 cites W2139368207 @default.
• W2910130606 cites W2337158505 @default.
• W2910130606 cites W2467633622 @default.
• W2910130606 cites W2611697423 @default.
• W2910130606 cites W2734648766 @default.
• W2910130606 cites W2763181211 @default.
• W2910130606 cites W2790982980 @default.
• W2910130606 doi "https://doi.org/10.1371/journal.pone.0210105" @default.
• W2910130606 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6328136" @default.
• W2910130606 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30629619" @default.
• W2910130606 hasPublicationYear "2019" @default.
• W2910130606 type Work @default.
• W2910130606 sameAs 2910130606 @default.
• W2910130606 citedByCount "36" @default.
• W2910130606 countsByYear W29101306062019 @default.
• W2910130606 countsByYear W29101306062020 @default.
• W2910130606 countsByYear W29101306062021 @default.
• W2910130606 countsByYear W29101306062022 @default.
• W2910130606 countsByYear W29101306062023 @default.
• W2910130606 crossrefType "journal-article" @default.
• W2910130606 hasAuthorship W2910130606A5009824461 @default.
• W2910130606 hasAuthorship W2910130606A5019572541 @default.
• W2910130606 hasAuthorship W2910130606A5027410574 @default.
• W2910130606 hasAuthorship W2910130606A5039731580 @default.
• W2910130606 hasAuthorship W2910130606A5044274628 @default.
• W2910130606 hasAuthorship W2910130606A5060071132 @default.
• W2910130606 hasAuthorship W2910130606A5079155294 @default.
• W2910130606 hasAuthorship W2910130606A5090161266 @default.
• W2910130606 hasBestOaLocation W29101306061 @default.
• W2910130606 hasConcept C126322002 @default.
• W2910130606 hasConcept C151730666 @default.
• W2910130606 hasConcept C187212893 @default.
• W2910130606 hasConcept C2777910003 @default.
• W2910130606 hasConcept C2779343474 @default.
• W2910130606 hasConcept C2781026528 @default.
• W2910130606 hasConcept C2781107259 @default.
• W2910130606 hasConcept C71924100 @default.
• W2910130606 hasConcept C86803240 @default.
• W2910130606 hasConceptScore W2910130606C126322002 @default.
• W2910130606 hasConceptScore W2910130606C151730666 @default.
• W2910130606 hasConceptScore W2910130606C187212893 @default.
• W2910130606 hasConceptScore W2910130606C2777910003 @default.
• W2910130606 hasConceptScore W2910130606C2779343474 @default.
• W2910130606 hasConceptScore W2910130606C2781026528 @default.
• W2910130606 hasConceptScore W2910130606C2781107259 @default.
• W2910130606 hasConceptScore W2910130606C71924100 @default.
• W2910130606 hasConceptScore W2910130606C86803240 @default.
• W2910130606 hasFunder F4320332718 @default.
• W2910130606 hasFunder F4320337355 @default.
• W2910130606 hasIssue "1" @default.
• W2910130606 hasLocation W29101306061 @default.
• W2910130606 hasLocation W29101306062 @default.
• W2910130606 hasLocation W29101306063 @default.
• W2910130606 hasLocation W29101306064 @default.
• W2910130606 hasLocation W29101306065 @default.
• W2910130606 hasOpenAccess W2910130606 @default.
• W2910130606 hasPrimaryLocation W29101306061 @default.
• W2910130606 hasRelatedWork W145137507 @default.
• W2910130606 hasRelatedWork W2008700437 @default.
• W2910130606 hasRelatedWork W2031952074 @default.
• W2910130606 hasRelatedWork W2049776456 @default.
• W2910130606 hasRelatedWork W2097753790 @default.
• W2910130606 hasRelatedWork W2368389588 @default.
• W2910130606 hasRelatedWork W2389988557 @default.
• W2910130606 hasRelatedWork W2474811327 @default.
• W2910130606 hasRelatedWork W2781494228 @default.
• W2910130606 hasRelatedWork W4251207176 @default.
• W2910130606 hasVolume "14" @default.
• W2910130606 isParatext "false" @default.
• W2910130606 isRetracted "false" @default.
• W2910130606 magId "2910130606" @default.
• W2910130606 workType "article" @default.